Single dose HPV vaccine in achieving global cervical cancer elimination

Abstract

Globally, cervical cancer remains a public health issue of increasing concern that could be addressed through the implementation of effective preventive measures such as human papillomavirus (HPV) vaccination, especially in low-income and middle-income countries (LMICs) in which fragile health systems have restrained the introduction and scaling-up of organised screening and treatment programmes. While most new cases and deaths from cervical cancer occur in LMICs, the worldwide HPV vaccine completion rate for girls aged 9–14 years (the primary target population for HPV vaccination) was only 17% in 2022.

Topics & Concepts